FTSE MIB
33.629,21 -107,19 (-0,32%) Dow Jones
38.675,68 +450,02 (+1,18%) Nasdaq
16.156,33 +315,37 (+1,99%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
77,99 -0,96 (-1,22%) Bitcoin EUR
59.151,13 +1.706,64 (+2,97%)
SCYNEXIS, Inc. (0L49.L)
| Chiusura precedente | 1,7300 |
| Aperto | 1,7900 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 1,7000 - 1,8100 |
| Intervallo di 52 settimane | 1,3488 - 3,8550 |
| Volume | |
| Media Volume | 2.340 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,57 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,2040 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate SCY-247 against a broad panel of fungal pathogens, including echinocandin-resistant Candida and Aspergillus, in an oral presentation at the 11th Congress on Trends in Medical Mycology (TIMM)
GlobeNewswireSCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
BREXAFEMME Carton BREXAFEMME Blister Pack JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the BREXAFEMME® tablets. During a review of manufacturing equipment and cleaning activities at a supplier, SCYNEXIS was ma
- GlobeNewswire
SCYNEXIS to Participate in September Investor Conferences
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that management will participate in the following investor conferences. Event:H.C. Wainwright 25th Annual Global Investment ConferenceFormat:Company presentation and 1-on-1 meetingsDate:September 12th, 2023Time:9:00 A.M. E.T.Location:New York, NYRegistration:Link Event:
